AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AVEO
Previous Symbol
CUSIP05358810
Phone617-588-1960
Debt
Debt-to-Equity RatioN/A
Current Ratio1.10
Quick Ratio1.10
Price-To-Earnings
Trailing P/E Ratio-12.50
Forward P/E Ratio-7.73
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.58 million
Price / Sales33.24
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.34) per share
Price / Book-5.91
Profitability
EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-590.02%
Return on EquityN/A
Return on Assets-54.94%
Miscellaneous
Employees19
Outstanding Shares125,350,000
Market Cap$258.21 million
OptionableOptionable
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.01. The biopharmaceutical company earned $2.47 million during the quarter, compared to analysts' expectations of $0.68 million. View AVEO Pharmaceuticals' Earnings History.
When is AVEO Pharmaceuticals' next earnings date?
What price target have analysts set for AVEO?
3 brokers have issued 12-month price targets for AVEO Pharmaceuticals' shares. Their predictions range from $5.00 to $9.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 251.8% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.
What is the consensus analysts' recommendation for AVEO Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVEO Pharmaceuticals.
Has AVEO Pharmaceuticals been receiving favorable news coverage?
News coverage about AVEO stock has trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting AVEO Pharmaceuticals?
AVEO Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totalling 20,523,871 shares, a decrease of 9.2% from the October 31st total of 22,599,619 shares. Based on an average daily volume of 4,912,677 shares, the days-to-cover ratio is presently 4.2 days. Currently, 21.2% of the shares of the company are short sold. View AVEO Pharmaceuticals' Current Options Chain.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Deciphera Pharmaceuticals (DCPH), Apellis Pharmaceuticals (APLS), TherapeuticsMD (TXMD), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), Puma Biotechnology (PBYI), Homology Medicines (FIXX), Athenex (ATNX), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), ImmunoGen (IMGN), Crinetics Pharmaceuticals (CRNX), Alder Biopharmaceuticals (ALDR) and Lexicon Pharmaceuticals (LXRX).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 53)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
- Dr. Michael N. Needle, Chief Medical Officer (Age 58)
- Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 59)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (15.71%), BlackRock Inc. (5.98%), Vanguard Group Inc (4.04%), Vanguard Group Inc. (4.04%), Bank of New York Mellon Corp (0.28%) and Fosun International Ltd (0.26%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which institutional investors are selling AVEO Pharmaceuticals stock?
Which institutional investors are buying AVEO Pharmaceuticals stock?
AVEO stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Fosun International Ltd, BlackRock Inc., Teachers Advisors LLC, MetLife Investment Advisors LLC, Vanguard Group Inc, Vanguard Group Inc. and Wells Fargo & Company MN. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $1.99.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $258.21 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
What is AVEO Pharmaceuticals' official website?
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
